ASH Leukemia Review: the more we learn, the less we know!

In this episode, Anthony and Bernie are joined by special guest, Dr. Justin Kaner from Weill Cornell Medicine, to discuss some of the most interesting ASH abstracts in leukemia in 2025! What abstracts should change practice? Listen to find out. Some of the abstracts discussed:PARADIGM: https://meetings-api.hematology.org/api/abstract/vmpreview/296881KMT2A Outcomes (MARROW Consortium and Othman, et al.): https://meetings-api.hematology.org/api/abstract/vmpreview/302582 and https://meetings-api.hematology.org/api/abstract/vmpreview/297333CLIA +/- Ven: https://meetings-api.hematology.org/api/abstract/vmpreview/302047FLT3i studies (and MRD): https://meetings-api.hematology.org/api/abstract/vmpreview/295719 and https://meetings-api.hematology.org/api/abstract/vmpreview/302699 and https://meetings-api.hematology.org/api/abstract/vmpreview/291322ALL GIMEMA Trial (blin + ponatinib): https://meetings-api.hematology.org/api/abstract/vmpreview/296532Menin inhibitor data